IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
Yoshiko Okita(The University of Osaka), Soichiro Shibui(Teikyo University Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Yasuji Miyakita, Makoto Ohno(Tokyo National Hospital), Koichi Ichimura(Hiroshima City Asa Citizens Hospital), Yoshitaka Narita(Unknown), Shintaro Fukushima(Kurume University), Takamasa Kayama(Yamagata University), Yuko Matsushita
Cited by 76
Related Papers
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
|Nature Genetics|2009|788
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
|Nature Communications|2019|372
Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis
|Annals of Internal Medicine|2020|332
Spatio-Temporal Meta-Graph Learning for Traffic Forecasting
|Proceedings of the AAAI Conference on Artificial Intelligence|2023|300
Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis
|International Journal of Radiation Oncology*Biology*Physics|2001|188